使用糖果的口服葡萄糖耐受性测试:一种甜蜜的解决方案来改善囊性纤维化儿童的查?
Caroline Weeks1, Sarah Jackson2, Nadir Demirel1,3
1Mayo Clinic Pediatric Endocrinology Cystic Fibrosis Center, Mayo Clinic, Rochester, MN 55905, USA.
Children (Basel, Switzerland)
|August 26, 2023
概括
一项新的研究表明,基于乳糖的糖果可能是患有囊性纤维化症 (CF) 的儿童口服葡萄糖耐受性测试 (OGTT) 的可行替代品. 这种糖果OGTT显示了与标准溶液相似的血糖结果,可能会提高粘附率.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 囊性纤维化研究 囊性纤维化研究
背景情况:
- 口服葡萄糖耐受性测试 (OGTT) 对患有囊性纤维化 (CF) 的9岁以上儿童至关重要.
- 医疗保健中心目前对标准OGTT协议的遵守程度不足于最佳水平.
- 确定改善患者坚持治疗的替代方法是临床优先事项.
研究的目的:
- 评估基于糖果的OGTT作为替代标准乳糖溶液的可行性.
- 为了比较儿童CF患者糖果和液体OGTT之间的血糖反应和参与者满意度.
主要方法:
- 一项试点研究涉及7名患有CF的儿童和青少年.
- 使用的是一种不含脂肪,纤维,凝和玉米糖的乳糖糖 (Nerds®).
- 糖果OGTT是在标准口服乳糖溶液OGTT后1-4天服用的.
主要成果:
- 120分钟后的葡萄糖水平在糖果和标准口服乳糖溶液之间是可比的 (p=0.8986).
- 该研究评估了血糖曲线和参与者的满意度.
- 一些参与者发现,在短时间内消耗大量糖果是具有挑战性的.
结论:
- 仔细选择的糖果替代品可能会在儿科CF患者中产生类似于标准OGTT的血糖结果.
- 参与者的偏好各不相同,有些人喜欢传统的解决方案,因为它容易消费.
- 基于糖果的OGTT值得进一步调查,作为加强CF管理遵守策略.
相关概念视频
Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Hypoglycemia and Glucagon
296
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
296
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184


